Reuters logo
Roche receives conditional EU approval for cancer drug
July 15, 2013 / 5:16 AM / 4 years ago

Roche receives conditional EU approval for cancer drug

ZURICH, July 15 (Reuters) - Roche said on Monday it had received conditional approval from the European Commission for Erivedge, a drug used to treat adults with basal cell carcinoma, a disfiguring form of skin cancer.

The approval makes Erivedge the first licensed medicine for patients in the European Union with this potentially life-threatening form of skin cancer, Roche said.

Reporting by Alice Baghdjian

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below